191 related articles for article (PubMed ID: 36979596)
1. Nanomaterials-Based Electrochemical Δ
Pazuki D; Ghosh R; Howlader MMR
Biosensors (Basel); 2023 Mar; 13(3):. PubMed ID: 36979596
[TBL] [Abstract][Full Text] [Related]
2. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.
Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW
Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoids in Oral Fluid: Limiting Potential Sources of Cannabidiol Conversion to Δ9- and Δ8-Tetrahydrocannabinol.
Coulter C; Wagner JR
J Anal Toxicol; 2021 Sep; 45(8):807-812. PubMed ID: 34137890
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of Δ8-THC, Δ9-THC, Cannabidiol and 10 Other Cannabinoids and Metabolites in Oral Fluid by HPLC-MS-MS.
Lin L; Amaratunga P; Reed J; Huang P; Lemberg BL; Lemberg D
J Anal Toxicol; 2022 Feb; 46(1):76-88. PubMed ID: 33270860
[TBL] [Abstract][Full Text] [Related]
5. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
[TBL] [Abstract][Full Text] [Related]
6. A crowdsourcing survey study on the subjective effects of delta-8-tetrahydrocannabinol relative to delta-9-tetrahydrocannabinol and cannabidiol.
Bergeria CL; Strickland JC; Spindle TR; Kalaba M; Satyavolu PU; Feldner M; Vandrey R; Bonn-Miller M; Peters EN; Weerts E
Exp Clin Psychopharmacol; 2023 Apr; 31(2):312-317. PubMed ID: 35467921
[TBL] [Abstract][Full Text] [Related]
7. Pilot clinical and pharmacokinetic study of Δ9-Tetrahydrocannabinol (THC)/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain.
Clarke S; Butcher BE; McLachlan AJ; Henson JD; Rutolo D; Hall S; Vitetta L
PLoS One; 2022; 17(10):e0270543. PubMed ID: 36240167
[TBL] [Abstract][Full Text] [Related]
8. Acute and chronic effects of cannabidiol on Δ⁹-tetrahydrocannabinol (Δ⁹-THC)-induced disruption in stop signal task performance.
Jacobs DS; Kohut SJ; Jiang S; Nikas SP; Makriyannis A; Bergman J
Exp Clin Psychopharmacol; 2016 Oct; 24(5):320-330. PubMed ID: 27690502
[TBL] [Abstract][Full Text] [Related]
9. A Critical Review of the Role of the Cannabinoid Compounds Δ
Jones É; Vlachou S
Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
[TBL] [Abstract][Full Text] [Related]
10. Use of cannabidiol (CBD) for the treatment of chronic pain.
Urits I; Gress K; Charipova K; Habib K; Lee D; Lee C; Jung JW; Kassem H; Cornett E; Paladini A; Varrassi G; Kaye AD; Viswanath O
Best Pract Res Clin Anaesthesiol; 2020 Sep; 34(3):463-477. PubMed ID: 33004159
[TBL] [Abstract][Full Text] [Related]
11. Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.
Sholler DJ; Spindle TR; Cone EJ; Goffi E; Kuntz D; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
J Anal Toxicol; 2022 May; 46(5):494-503. PubMed ID: 34089060
[TBL] [Abstract][Full Text] [Related]
12. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats.
Parker LA; Burton P; Sorge RE; Yakiwchuk C; Mechoulam R
Psychopharmacology (Berl); 2004 Sep; 175(3):360-6. PubMed ID: 15138755
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Use of Δ9-THC and Cannabidiol: Evaluation of a New Extraction Procedure for the Preparation of Cannabis-based Olive Oil.
Morini L; Porro G; Liso M; Groppi A
Curr Pharm Biotechnol; 2017; 18(10):828-833. PubMed ID: 29189144
[TBL] [Abstract][Full Text] [Related]
14. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
15. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
16. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
[TBL] [Abstract][Full Text] [Related]
17. Acute effects of Δ
Greenwood LM; Broyd SJ; van Hell HH; Todd J; Jones A; Murray RM; Croft RJ; Michie PT; Solowij N
Psychopharmacology (Berl); 2022 May; 239(5):1409-1424. PubMed ID: 34719731
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations.
Moore CF; Weerts EM
Psychopharmacology (Berl); 2022 May; 239(5):1397-1408. PubMed ID: 34652500
[TBL] [Abstract][Full Text] [Related]
19. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
20. Homegrown perceptions about the medical use and potential abuse of CBD and THC.
McFadden BR; Malone T
Addict Behav; 2021 Apr; 115():106799. PubMed ID: 33387977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
